2m 2m 2m 2m 2m 2m 2m
KALARIS THERAP (KLRS)
NASDAQ
$4.74+$0.02 (+0.42%)
Price as of Jun 03, 2026 6:19 PM EDT- $125.4MMarket Cap
- 50.97%1-Year Change
- BiotechnologyIndustry
KALARIS THERAP (KLRS)
$4.74+$0.02 (+0.42%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | 0 -100.00% | 500,000 N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 +100.00% | -500,000 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -100,000 -99.19% | -12.3M -90.73% | -133.1M +11.95% | -118.9M -1.54% | |
Depreciation and Amortization Expense | 13,000 -96.73% | 398,000 0.00% | 398,000 -44.95% | 723,000 +282.54% | |
Total Operating Expenses | 46.2M -29.48% | 65.4M -67.26% | 199.9M +16.76% | 171.2M +0.81% | |
Operating Profit | -46.2M -29.48% | -65.4M -67.26% | -199.9M +16.76% | -171.2M +0.81% | |
Interest Income | N/A N/A | 5.5M -4.33% | 5.7M +205.65% | 1.9M +42.66% | |
Interest Expense | -1.4M N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | -1.4M -125.23% | 5.5M -4.33% | 5.7M +205.65% | 1.9M +42.66% | |
Total Nonoperating Income and Expense | 2.7M +128.84% | 1.2M -67.26% | 3.6M +932.19% | 351,000 +114.31% | |
Income before Taxes | -46.2M -21.47% | -58.8M -69.16% | -190.5M +12.76% | -169.0M -1.16% | |
Income Taxes | 0 N/A | 0 +100.00% | -126,000 -52.45% | -265,000 -126.32% | |
Extraordinary Items | N/A N/A | 0 -100.00% | 18.6M N/A | N/A N/A | |
Net Income | -43.4M -26.09% | -58.8M -69.14% | -190.4M +12.87% | -168.7M -1.89% | |
Net Income from Continuing Operations Applicable to Common | -43.4M -26.09% | -58.8M -69.16% | -190.5M +12.76% | -169.0M -1.16% | |
Basic EPS and Net Income | -2.85 -75.70% | -11.73 +540.98% | -1.83 -16.82% | -2.20 -19.71% | |
Diluted EPS and Net Income | -2.85 -75.70% | -11.73 +540.98% | -1.83 -16.82% | -2.20 -19.71% | |
Basic Weighted Average Shares | 15.3M +204.84% | 5.0M -95.19% | 104.1M +35.75% | 76.7M +22.10% | |
Diluted Weighted Average Shares | 15.3M +204.84% | 5.0M -95.19% | 104.1M +35.75% | 76.7M +22.10% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 98.1M -17.11% | 118.3M +31.26% | 90.1M -15.05% | 106.1M -47.39% | |
Short-Term Investments | 19.9M N/A | 0 -100.00% | 93.8M -26.53% | 127.7M +174.87% | |
Cash and Cash Equivalents and Short-Term Investments | 118.0M -0.26% | 118.3M -35.69% | 183.9M -21.32% | 233.8M -5.77% | |
Total Current Assets | 118.8M +0.22% | 118.5M -36.82% | 187.6M -22.80% | 243.1M -4.06% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | 1.0M +257.30% | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | 930,000 0.00% | 930,000 -39.96% | |
Total Long-Term Assets | 953,000 +681.15% | 122,000 0.00% | 122,000 -80.07% | 612,000 -44.46% | |
Total Assets | 121.7M +2.69% | 118.5M -37.87% | 190.8M -31.14% | 277.1M -3.32% | |
Income Taxes Payable | N/A N/A | N/A N/A | 128,000 0.00% | 128,000 -87.29% | |
Total Short-Term Debt | 0 N/A | N/A N/A | N/A N/A | 56,000 -96.79% | |
Total Current Liabilities | 9.7M +85.42% | 5.2M -81.53% | 28.4M +16.55% | 24.3M -35.70% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.1M -93.20% | 16.6M 0.00% | 16.6M -41.01% | 28.2M +20.22% | |
Total Liabilities | 42.9M +719.28% | 5.2M -88.36% | 45.0M -14.36% | 52.6M -14.30% | |
Retained Earnings | -160.0M -77.62% | -715.0M +8.96% | -656.2M +40.88% | -465.8M +56.79% | |
Total Stockholders Equity | 78.8M -30.44% | 113.3M -22.28% | 145.8M -35.07% | 224.5M -0.33% | |
Total Shares Outstanding | 22.9M +354.36% | 5.0M -95.58% | 114.1M +22.62% | 93.1M +46.45% | |
Cash Flow | |||||
Cash from Operating Activities | -38.4M -43.33% | -67.7M -45.60% | -124.5M -12.39% | -142.1M +33.61% | |
Capital Expenditures | 200,000 N/A | N/A N/A | N/A N/A | 26,000 0.00% | |
Cash from Investing Activities | -19.7M -120.76% | 95.0M +150.10% | 38.0M +147.20% | -80.5M -143.27% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 155.0M +738,028.57% | 21,000 -99.97% | 70.5M -44.48% | 127.0M +54,624.57% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -36.16% -4.84% | -38.00% -53.32% | -81.40% +35.98% | -59.86% +14.42% | |
Return on Equity | -45.22% -0.32% | -45.37% -55.89% | -102.85% +37.09% | -75.02% +26.15% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 12.23 -45.95% | 22.63 +242.09% | 6.61 -33.76% | 9.99 +49.21% | |
Cash Ratio | 10.09 -55.29% | 22.58 +610.69% | 3.18 -27.12% | 4.36 -18.18% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow